{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:18:30Z","timestamp":1790288310634,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2023,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Anti\u2010G\n                    <jats:sub>D2<\/jats:sub>\n                    monoclonal antibodies (mAb) improve the prognosis of high\u2010risk neuroblastoma (HR\u2010NB). Worldwide experience almost exclusively involves toddlers and older patients treated after multimodality or second\u2010line therapies, that is, many months postdiagnosis. In contrast, at our center, infants received anti\u2010G\n                    <jats:sub>D2<\/jats:sub>\n                    mAbs because this immunotherapy started during or immediately after induction chemotherapy. We now report on the feasibility, safety, and long\u2010term survival in this vulnerable age group. Thirty\u2010three HR\u2010NB patients were\u2009&lt;19\u2009months old when started on 3F8 (murine mAb; n\u00a0=\u00a021) or naxitamab (humanized\u20103F8; n\u00a0=\u00a012), with 30\u2033 to 90\u2033 intravenous infusions. Patients received analgesics and antihistamines. Common toxicities (pain, urticaria, cough) were manageable, allowing outpatient treatment. Capillary leak, posterior reversible encephalopathy syndrome, and mAb\u2010related long\u2010term toxicities did not occur. Two 3F8 cycles were aborted due to bradycardia (a preexisting condition) and asthmatic symptoms, respectively. One patient received \u00bd dose of Day 1 naxitamab because of hypotension; full doses were subsequently administered. Post\u2010mAb treatments included chemotherapy, radiotherapy, and anti\u2010NB vaccine. Among 3F8 patients, 17\/21 are in complete remission off all treatment at 5.6+ to 24.1+ (median 13.4+) years from diagnosis. Among naxitamab patients, 10\/12 remain relapse\u2010free post\u2010mAb at 1.7+ to 4.3+ (median 3.1+) years from diagnosis. Toxicity was similar with short outpatient infusions and matched that observed with these and other anti\u2010G\n                    <jats:sub>D2<\/jats:sub>\n                    mAbs in older patients. These findings were reassuring given that naxitamab is dosed &gt;2.5\u00d7 higher (~270\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    \/cycle) than 3F8, dinutuximab, and dinutuximab beta (70\u2010100\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    \/cycle). HR\u2010NB in infants proved to be highly curable.\n                  <\/jats:p>","DOI":"10.1002\/ijc.34233","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T11:34:20Z","timestamp":1659353660000},"page":"259-266","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immunotherapy with\n                    <scp>\n                      anti\u2010G\n                      <sub>D2<\/sub>\n                    <\/scp>\n                    monoclonal antibody in infants with high\u2010risk neuroblastoma"],"prefix":"10.1002","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8916-0697","authenticated-orcid":false,"given":"Brian H.","family":"Kushner","sequence":"first","affiliation":[{"name":"Department of Pediatrics Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakeel","family":"Modak","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Kramer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Basu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Iglesias\u2010Cardenas","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen S.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai\u2010Kong V.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911123"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30070-0"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-21"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/1096-911X(20010101)36:1<227::AID-MPO1055>3.0.CO;2-U"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.3807"},{"key":"e_1_2_12_7_1","first-page":"e1016704","article-title":"Prolonged progression\u2010free survival after consolidating second or later remissions of neuroblastoma with anti\u2010GD2 immunotherapy and isotretinoin: a prospective phase II study","volume":"4","author":"Kushner BH","year":"2015","journal-title":"Onco Targets Ther"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28851"},{"key":"e_1_2_12_9_1","first-page":"477","article-title":"Humanizing murine IgG3 anti\u2010GD2 antibody m3F8 substantially improves antibody\u2010dependent cell\u2010mediated cytotoxicity while retaining targeting in vivo","volume":"1","author":"Cheung NK","year":"2012","journal-title":"Onco Targets Ther"},{"key":"e_1_2_12_10_1","first-page":"e1358331","article-title":"Phase I trial of anti\u2010GD2 monoclonal antibody hu3F8 plus GM\u2010CSF: impact of body weight, immunogenicity and anti\u2010GD2 response on pharmacokinetics and survival","volume":"6","author":"Cheung IY","year":"2017","journal-title":"Onco Targets Ther"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4005"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-836518"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.3564"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2575-9"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2955-9"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01355"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.101"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6393"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20513"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70309-7"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.11642"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1452"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00203"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001992"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.571"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705253"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.0177"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.09.014"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-009-0038-7"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25232"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33044"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01892"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-021-00469-9"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29663"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.34233","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.34233","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.34233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T03:08:22Z","timestamp":1692673702000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.34233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1,15]]}},"alternative-id":["10.1002\/ijc.34233"],"URL":"https:\/\/doi.org\/10.1002\/ijc.34233","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"assertion":[{"value":"2022-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}